The Effect of Nanocurcumin Supplementation on Inflammatory and Biochemical Indicators in Hospitalized Patients With COVID‐19: A Randomized Controlled Clinical Trial

• Published in: International journal of clinical practice (Esher) 2024-01, Vol.2024 (1)
• Main Authors: Ahmadi, Sedigheh, Mohit, Mohsen, Mehrabi, Zeinab, Heydari, Mohammad Reza, Faraji, Seyed Nooreddin, Yaghoubi, Shoeleh, Zare, Morteza, Masoumi, Seyed Jalil
• Format: Article
• Language: English
• Subjects: Acute phase proteins; Alanine transaminase; Anticoagulants; Antiviral agents; Aspartate aminotransferase; Biochemical markers; C-reactive protein; Clinical trials; Consent; Coronaviruses; COVID-19; Cytokine storm; Disease; Epidemics; Erythrocyte sedimentation rate; Food; Hemoglobin; Hospitalization; Inflammation; Interleukin 6; L-Lactate dehydrogenase; Leukocytes (neutrophilic); Lymphocytes; Nutrition research; Nutritionists; Patients; Placebos; Severe acute respiratory syndrome coronavirus 2; Supplements; Tumor necrosis factor-TNF; Viruses
• ISSN: 1368-5031; 1742-1241
• DOI: 10.1155/ijcp/6675459

Background: The prior studies showed that nanocurcumin (NC) has potential anti‐viral properties against a wide range of viral infections, making it a promising candidate for treating COVID‐19. This study aimed to investigate the effect of NC supplementation on the acute phase proteins, including interleukin‐6 (IL‐6), C‐reactive protein (CRP), albumin (ALB) and Erythrocyte Sedimentation Rate (ESR), and biochemical markers including lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine transaminase (ALT) and complete blood cells (CBC) in the hospitalized patients with Coronavirus disease 2019 (COVID‐19). Methods and Materials: In a double‐blind placebo‐controlled clinical trial conducted at Ali‐Asghar Hospital of Shiraz University of Medical Sciences, 76 COVID‐19 patients with mild to moderate disease severity were randomly assigned to two groups. All patients received the national treatment guideline for COVID‐19. The intervention group was administered 160 mg/day of NC for a period of 2 weeks. Blood samples were obtained at the start and the end of the research, and nutritional consumption was determined using a 24 h dietary recall. Results: The mean age of participants in the NC and placebo groups was 54.69 ± 13.44 and 53.94 ± 11.62 years, respectively. In the NC group, compared with placebo group, the levels of IL‐6 ( p = 0.017) and LDH ( p = 0.004) was significantly reduced. There was no significant difference in the mean changes of AST ( p = 0.197), ALT ( p = 0.086), ALB ( p = 0.560), CRP ( p = 0.197), ESR ( p = 0.298), hemoglobin (Hb) ( p = 0.372), white blood cells (WBC) ( p = 0.995), neutrophils ( p = 0.264), and lymphocyte ( p = 0.418) between two groups. Conclusion: According to the research results, it seems that adding NC supplementation to the treatment plan for COVID‐19 patients who are hospitalized and have mild to moderate illness severity might possibly reduce inflammation. Trial Registration: ClinicalTrials.gov identifier: IRCT20211126053183N1 .